Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q2 2022 · 10-Q
Revenue$10.41M$10.41M+37.7% vs Q2 2021 Net Income-$12.74M-$12.74MN/M vs Q2 2021 EPS Diluted-$0.88-$0.88N/M vs Q2 2021 Gross Profit$6,550,000+28.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$11,686,000N/M Free Cash Flowderived-$11,886,000N/M Margins · derivedGross margin62.9%−4.4 pt vs Q2 2021
Operating margin-98.4%−1.6 pt vs Q2 2021
Net margin-122.4%−13.2 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end